Umlaut.bio
Key Facts
| Invested since | 2024 |
| Based in | Heidelberg |
About the company
Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – chemically modified RNA nucleotides. These play a crucial role in gene regulation and are of great importance, for example, in cancer cells. There, modified tRNAs protect protein-coding mRNAs from degradation and thus promote tumor growth. Therapeutic modalities that specifically address this mechanism could be able to selectively prevent the growth of cancer cells. This approach promises a disruptive novel form of cancer therapy that could offer a new, gentler treatment option for many patients.
Do you want to
know more about this company?
Umlaut.bio in the news
More startups from Life Sciences
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular …
to HepaRegeniX
heartbeat ONE provides a streamlined patient management tool for health care facilities of all sizes. It offers intelligent evaluations of diagnostics and treatment methods. It supports the preparation, documentation and …
to heartbeat medical
Breakthrough technology for the oral delivery of biologics in a standard size capsule
to Biograil
Exit
Sierra Sensors is combining state of the art label-free detection with cutting edge microfluidic sample delivery, sensor design, and automation, to supply researchers with high performance analytical biosensors.
to Sierra Sensors
stimOS develops and markets (r)evolutionary technologies that functionalize implant materials and offers these technologies to implant manufacturers. With the product lines spineFuse and smartDENT the company develops own biosimilar implant …
to stimOS
Intelligent fluids GmbH is designing innovative high performance cleaning fluids for industrial application that are unique in the world. These intelligent fluids® are based on a groundbreaking, patented technology that …
to intelligent fluids
Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary …
to mbiomics
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
to Lipocalyx
Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility …
to Tacalyx
MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®. Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases …
to MDTB Cell Manufacturing
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
to Lindis Blood Care
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal …
to Alentis